Central Garden & Pet Stock (NASDAQ: CENTA)

Central Garden & Pet (NASDAQ:CENTA) Stock

Central Garden & Pet

Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.

Central Garden & Pet Company - Class A Common Stock Nonvoting

Central Garden & Pet Co

Centamin PLC

Centaur Media PLC

CENTAURUS ENERGY INC by Centaurus Energy Inc.

Centaurus Energy Inc

CENTAURUS METALS LTD ORD by Centaurus Metals Ltd.

Centaurus Metals Ltd

Central Garden &amp; Pet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cent#NASDAQ">CENT</a>) FY2025 expected to be more than $2.20 vs $2.36 Est.

News

Guidance

CENT

CENTA

Central Garden & Pet FY2025 EPS Expected To Be More Than  $2.20 vs $2.36 Est

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.93 by 11.83 percent. This is a 5.05 percent increase over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $833.54 million which missed the analyst consensus estimate of $879.02 million by 5.17 percent. This is a 7.39 percent decrease over sales of $900.09 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Central Garden & Pet Q2 Adj. EPS $1.04 Beats $0.93 Estimate, Sales $833.54M Miss $879.02M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Truist Securities analyst Bill Chappell downgrades Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) from Buy to Hold and lowers the price target from $40 to $35.

Downgrades

Price Target

Analyst Ratings

Truist Securities Downgrades Central Garden & Pet to Hold, Lowers Price Target to $35

JP Morgan analyst Andrea Faria maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $34 to $31.

JP Morgan Maintains Neutral on Central Garden & Pet, Lowers Price Target to $31

WIIM

ABEV

ANDE

BRBR

BRFS

CART

CASY

CELH

COCO

COKE

COST

COTY

FIZZ

Fomento Economico Mexicano S.A.B. De C.V.

FRPT

HFFG

HNST

IPAR

ISPR

MDLZ

MGPI

MNST

PFGC

PSMT

SNYR

TBBB

UNFI

UPXI

USFD

USNA

WALD

WEST

Shares of consumer staple companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

Central Garden shares are trading higher after the company reported better-than-expected Q1 financial results.

Central Sees FY25 Non-GAAP EPS $2.20+ vs $2.25 Est.

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 2000 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $656.000 million which beat the analyst consensus estimate of $629.720 million by 4.17 percent. This is a 3.38 percent increase over sales of $634.533 million the same period last year.

Central Garden & Pet Q1 2025 GAAP EPS $0.21 Beats $0.00 Estimate, Sales $656.000M Beat $629.720M Estimate

ALGN

AMSC

APPS

ARAY

ARCC

ARES

ASGN

ASYS

BARK

BSBR

CMRE

CNMD

CNXN

CPAY

CPRI

CRTO

CTSH

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

Earnings Scheduled For February 5, 2025

JP Morgan analyst Andrea Faria maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $32 to $31.

Argus Research analyst John Eade downgrades Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) from Buy to Hold.

Argus Research Downgrades Central Garden & Pet to Hold

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.02 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Central Garden & Pet Q4

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:02 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.02, resulting in a 0.0% increase change in the share price the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Central Garden & Pet Earnings Analysis: Q4 Recap

The earnings results for Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) for Q4 were made public on Monday, November 25, 2024 at 04:02 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Central Garden & Pet Q4 Earnings Assessment

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.02 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Central Garden & Pet Q4

Central Garden & Pet shares are trading lower after the company reported Q4 sales that missed analyst estimates, despite better-than-expected adjusted EPS.

Central Garden & Pet Company Sees FY25 Non-GAAP EPS $2.20 Or Better vs $2.44 Est.

Central Garden & Pet Q4 2024 Adj. EPS $(0.18) Beats $(0.20) Estimate, Sales $669M Miss $706.184M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly loss at $0.10 per share on revenue of $4.12 million. 
• Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) is estimated to report earnings for its second quarter. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $227.49 million. 
• Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $68.00 million. 
• Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $1.58 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.16 per share on revenue of $5.95 million. 
<h3>Companies Reporting After The Bell</h3>
• BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $776.51 million. 
• Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $1.67 billion. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $706.77 million. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $707.30 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its third quarter. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly loss at $0.02 per share on revenue of $69.82 million. 
• Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $404.09 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $232.90 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $40.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.31 billion. 
• Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $1.16 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is likely to report quarterly earnings at $1.25 per share on revenue of $812.95 million. 
• Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) is expected to report quarterly earnings at $0.67 per share on revenue of $324.70 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $199.08 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $407.00 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $36.14 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $48.95 million. 
• Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is likely to report quarterly loss at $1.16 per share on revenue of $17.93 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

BBWI

BLRX

CRGO

ENTA

FLNC

HSAI

LESL

PFLT

PNNT

SMTC

SUPV

UXIN

Earnings Scheduled For November 25, 2024

Press Releases

Ferry-Morse Welcomes Spring with Garden Get-Together Video Series; Shares 25% off Discount with Series

Comments

Central Garden & Pet

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL